These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33784965)

  • 1. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)
    Kritmetapak K; Losbanos L; Berent TE; Ashrafzadeh-Kian SL; Algeciras-Schimnich A; Hines JM; Singh RJ; Kumar R
    BMC Nephrol; 2021 Mar; 22(1):114. PubMed ID: 33784965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.
    Bushinsky DA; Spiegel DM; Yuan J; Warren S; Fogli J; Pergola PE
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):103-110. PubMed ID: 30381412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study.
    Stein MS; Ward GJ; Butzkueven H; Kilpatrick TJ; Harrison LC
    Mol Med; 2018 May; 24(1):27. PubMed ID: 30134801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.
    Chudek J; Kocełak P; Owczarek A; Bożentowicz-Wikarek M; Mossakowska M; Olszanecka-Glinianowicz M; Wiecek A
    Nephrol Dial Transplant; 2014 Sep; 29(9):1757-63. PubMed ID: 24729016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
    Ginsberg C; Craven TE; Chonchol MB; Cheung AK; Sarnak MJ; Ambrosius WT; Killeen AA; Raphael KL; Bhatt UY; Chen J; Chertow GM; Freedman BI; Oparil S; Papademetriou V; Wall BM; Wright CB; Ix JH; Shlipak MG;
    Clin J Am Soc Nephrol; 2018 Dec; 13(12):1816-1824. PubMed ID: 30425104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
    de Jong MA; Petrykiv SI; Laverman GD; van Herwaarden AE; de Zeeuw D; Bakker SJL; Heerspink HJL; de Borst MH
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):66-73. PubMed ID: 30559106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.
    Christodoulou M; Aspray TJ; Piec I; Fraser WD; Schoenmakers I;
    Age Ageing; 2024 May; 53(5):. PubMed ID: 38770543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia.
    Whyte MP; Zhang F; Wenkert D; Mumm S; Berndt TJ; Kumar R
    Bone; 2020 May; 134():115300. PubMed ID: 32112990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
    Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early renal impairment affects hormonal regulators of calcium and bone metabolism and Wnt signalling and the response to vitamin D supplementation in healthy older adults.
    Christodoulou M; Aspray TJ; Piec I; Washbourne C; Tang JCY; Fraser WD; Schoenmakers I;
    J Steroid Biochem Mol Biol; 2023 May; 229():106267. PubMed ID: 36739953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.